- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04548765
Evaluation of Letters Promoting Colorectal Cancer Testing
Evaluation of Letters Enhanced With Behavioral Nudges to Promote Colorectal Cancer Testing Through Fecal Immunochemical Tests or Colonoscopies
Study Overview
Status
Conditions
Detailed Description
Colorectal cancer (CRC) is the third most common cancer diagnosed in the US. Mailing fecal immunochemical (FIT) kits to at-risk patients is an effective way of increasing CRC testing uptake, as this test can be done at home and is less intrusive compared to colonoscopies. As part of an existing program, the health system mails FIT kits to eligible patients each year. Although this test needs to be conducted annually, not everyone who receives the test kit returns the kits for processing. In this study, the researchers aim to test different letters with the goal of encouraging the use of FIT kits or scheduling a colonoscopy.
As part of this study, the kits are mailed with everything the patient will need to conduct the test at home and mail a sample back to the hospital. It also includes an introductory letter informing the patient about the program and inviting them to use the kit. The researchers are comparing a standard version of the introductory letter against 3 versions that include different combinations of behavioral nudges, specifically framing effects (loss, default, decoy) and fear appeals.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17822
- Geisinger
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Enrollment in Medicare Health Maintenance Organization (HMO) and Preferred Provider Organization (PPO; age 65 and older) or Commercial HMO in one large employer's group
- Has a flag indicating that the person is due for a colon cancer screening
Exclusion Criteria:
- Members who are on the do not contact list at Geisinger Health Plan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard Letter
The standard letter describes the importance of getting screened and instructs recipients how to use the FIT kit for screening at home.
|
Recipients receive a letter promoting CRC screening.
|
Experimental: Letter with Risks
The standard letter is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; it also explains why test kits are being sent to disarm skepticism about the program.
|
Recipients receive a letter promoting CRC screening.
The letter is enhanced with language that frames the situation in terms of losses.
It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
|
Experimental: Letter with Risks and Options
In addition to the enhancements added by the letter with risks, the letter also includes a table comparing FIT kit and colonoscopy.
Presenting different screening options allows recipients to make the choice that best suits them.
In addition, presenting multiple options increases the chance that recipients get screened in one way or another.
|
Recipients receive a letter promoting CRC screening.
The letter is enhanced with language that frames the situation in terms of losses.
It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
The pros and cons for screening with FIT kits and colonoscopy are presented.
By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer).
In this situation, inaction is no longer the default option.
Changing the default option increases the chance that the FIT kit is used.
In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed.
Inaction is presented as a decoy, which has worse outcomes than either of the screening options.
Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
|
Experimental: Letter with Risks, Options, and Consequences for Inaction
In addition to the enhancements added by the letter with risk, the comparison table includes comparisons of the consequences of getting screened vs. waiting for symptoms to appear.
|
Recipients receive a letter promoting CRC screening.
The letter is enhanced with language that frames the situation in terms of losses.
It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed.
Inaction is presented as a decoy, which has worse outcomes than either of the screening options.
Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FIT Kit Return at 6 months
Time Frame: 6 months from intervention start date
|
Binary variable indicating whether a valid FIT kit was returned for testing
|
6 months from intervention start date
|
Colonoscopy Ordered at 6 months
Time Frame: 6 months from intervention start date
|
Binary variable indicating whether a colonoscopy was ordered
|
6 months from intervention start date
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FIT Kit Return at 12 months
Time Frame: 12 months from intervention start date
|
Binary variable indicating whether a valid FIT kit was returned for testing (a longer time frame allows for late responses)
|
12 months from intervention start date
|
Colonoscopy Ordered at 12 months
Time Frame: 12 months from intervention start date
|
Binary variable indicating whether a colonoscopy was ordered (a longer time frame allows for late responses)
|
12 months from intervention start date
|
FIT Kit Result
Time Frame: 12 months from intervention start date
|
Binary variable indicating whether the test was positive or negative (if FIT kit was returned)
|
12 months from intervention start date
|
Colonoscopy Completed
Time Frame: 12 months from intervention start date
|
Binary variable indicating whether the colonoscopy was completed (if colonoscopy was ordered)
|
12 months from intervention start date
|
Colonoscopy Result
Time Frame: 12 months from intervention start date
|
Binary variable indicating whether the test was positive or negative (if colonoscopy was completed)
|
12 months from intervention start date
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-0510
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer Colorectal
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
Clinical Trials on Letter
-
The Cleveland ClinicCompletedConflicts of Interest
-
Public Health EnglandWithdrawnInfluenza, Human
-
University of Paris 5 - Rene DescartesHotel Dieu Hospital; Société de Formation Thérapeutique du Généraliste; Adeca 75Unknown
-
Case Western Reserve UniversityNational Institute of Dental and Craniofacial Research (NIDCR); University... and other collaboratorsCompleted
-
University of California, San FranciscoActive, not recruiting
-
Nantes University HospitalActive, not recruiting
-
Aalborg University HospitalCompletedRecruitment, Invitation Letters, Patients With SchizophreniaDenmark
-
Northwestern UniversityAgency for Healthcare Research and Quality (AHRQ)TerminatedColorectal CancerUnited States
-
Centre For International HealthMakerere UniversityCompleted
-
Swansea UniversityAbertawe Bro Morgannwg University Health BoardRecruitingPelvic Floor DysfunctionsUnited Kingdom